Peptide receptor radionuclide therapy for neuroendocrine tumours
- 58 Downloads
Neuroendocrine tumours (NETs) are a heterogeneous group of tumours that arise in different tissues and organs and have an endocrine and neurological interface that differentiates them into a stand-alone entity. One of their interesting and unique criteria is the overexpression of somatostatin receptors (SSRs) on their cell membrane, which has allowed for specific diagnostic imaging techniques and targeted therapy like peptide receptor radionuclide therapy (PRRT).
The aim of this study is to provide a literature review summarizing the latest available studies concerning the use of PRRT in treatment of neuroendocrine tumours including patient selection, the choice of PRPP, efficacy, side effects, and complications.
A comprehensive search strategy was used based on SCOPUS and PubMed databases. We considered all studies published in English evaluating the use of PRRT (177Lu-Dotatate and 90Y-Dotatate) in treatment of NETs and its effectiveness and side effects and complications.
PRRT was found to be effective as monotherapy or in combination with other therapies. 90Yttrium may be more appropriate for larger tumour lesions, while 177Lutetium is more appropriately used for smaller ones. A combination therapy with 90Yttrium and 177Lutetium has been suggested for variable sized lesions. Mild acute side effects were reported more in 177Lutetium, while sub-acute and long-term side effects are more with 90Yttrium. Heamatotoxicity is usually mild and reversible and only < 15% may progress into severe toxicity. Renal toxicity was greatly reduced to < 3% by kidney protective measures.
PRRT is well-tolerated and effective treatment modality for non-operable and/or metastatic neuroendocrine tumours. Side effects are usually mild and reversible. More work needs to be done regarding standardization of dosing, timing, and patient selection criteria and ways of follow-up to obtain the maximum potential benefit.
KeywordsPRRT Neuroendocrine tumours 177Lu-Dotatate 90Y-Dotatate SSTR 1–5 68Ga-Dotatate PET/CT
SY: content planning, literature search and review, manuscript writing, and editing. SA: literature search and review, manuscript writing, and editing. AA-N: content planning, literature search and review, manuscript writing, and editing.
Compliance with ethical standards
Conflict of interest
The authors, Siraj Yusuf, Shahad Alsadik, and Adil AL-Nahhas, have no conflict of interest to declare.
This article does not contain any studies with human or animal subjects performed by the any of the authors.
- 2.Public Health England (2016) Incidence and survival in neuroendocrine tumours and neuroendocrine carcinomas (NETs/NECs) in England, 2013–2014, PHE publications gateway number: 2016360Google Scholar
- 7.Aktolun C, Goldsmith SJ (2015) Nuclear oncology. Wolters Kluwer, PhiladelphiaGoogle Scholar
- 15.Mestier LD, Dromain C, Dassignies G et al (2013) Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. Endocr Relat Cancer 21(3):R105-20Google Scholar
- 19.Mojtahedi A, Thamake S, Tworowska I et al (2014) The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. Am J Nucl Med Mol Imaging 4:426e34Google Scholar
- 29.Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH et al (2006) Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36(2):147–156CrossRefPubMedGoogle Scholar
- 31.Pfeifer AK, Gregersen T, Gronbaekk H, Hansen CP, Muller-Brand J, Herskind Bruun K et al (2011) Peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology 93(3):189–196CrossRefPubMedGoogle Scholar
- 32.Cwikla JB, Sankowski A, Seklecka N, Buscombe JR, Nasierowska-Guttmejer A, Jeziorski KG et al (2010) Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol 21(4):787–794CrossRefPubMedGoogle Scholar
- 37.Tessa B, Jaap T, Casper V, Gaston F, Richard F, Wouter D et al (2016) Peptide receptor radionuclide therapy of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 30:103e114Google Scholar
- 48.Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M et al (2008) Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 35(10):1847–1856CrossRefPubMedGoogle Scholar
- 52.Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M et al (2016) ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103(2):153–171CrossRefPubMedPubMedCentralGoogle Scholar
- 66.Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R et al (2014) (213)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging 41(11):2106–2119CrossRefPubMedPubMedCentralGoogle Scholar